KTE-X19 bags FDA Priority Review in mantle cell lymphoma

11th February 2020 Uncategorised 0

The EMA also recently validated a Marketing Authorisation Application for the drug.

More: KTE-X19 bags FDA Priority Review in mantle cell lymphoma
Source: News